These in vitro and in vivo experimental results indicate that using Schottky heterojunction to upregulate Bmal1 yields superior therapeutic effects for AT compared to using pure ROS scavenger Nb2C. Furthermore, the utilization of Bmal1 enhancers represents a promising and potential treatment modality for AT. Here, BMAL1 is linked to ataxia telangiectasia.